Dashboard
Manage Tickers

JNJ


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cantor-fitzgerald-reiterates-overweight-on-johnson--johnson-maintains-215-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/16/2024 12:20:14

Cantor Fitzgerald analyst Louise Chen reiterates Johnson & Johnson (NYSE:JNJ) with a Overweight and maintains $215 price...

reported-saturday-johnson--johnson-shares-new-data-on-rybrevant-in-metastatic-colorectal-cancer-at-esmo-congress
Reported Saturday, Johnson & Johnson Share...
09/16/2024 07:01:48

 Johnson & Johnson (NYSE:JNJ) today announced new data from the Phase 1b/2 OrigAMI-1 study, which showed RYBREVANT® (amivan...

reported-sunday-johnson--johnson-reveals-new-data-on-tar-200-for-bladder-cancer-treatment
Reported Sunday, Johnson & Johnson Reveals...
09/16/2024 06:59:25

Johnson & Johnson (NYSE:JNJ) announced today additional results from the pivotal Phase 2b SunRISe-1 study, supporting the s...

johnson--johnsons-tar-200-plus-cetrelimab-nearly-doubles-cancer-response-rate-in-bladder-cancer-phase-2-trial
Johnson & Johnson's TAR-200 Plus Cetrelima...
09/16/2024 06:57:19

Johnson & Johnson (NYSE:JNJ) announced today interim data from the ongoing Phase 2 SunRISe-4 study showing neoadjuvant trea...

unpacking-the-latest-options-trading-trends-in-johnson--johnson
Unpacking the Latest Options Trading Trend...
09/12/2024 20:49:22

competitor-analysis-evaluating-johnson-amp-johnson-and-competitors-in-pharmaceuticals-industry
Competitor Analysis: Evaluating Johnson &a...
09/12/2024 15:00:49

johnson--johnson-seeks-first-eu-approval-of-nipocalimab-to-treat-broad-population-of-patients-living-with-antibody-positive-generalised-myasthenia-gravis
Johnson & Johnson Seeks First EU Approval ...
09/12/2024 14:12:54

-Reuters

how-to-earn-500-a-month-from-johnson--johnson-stock
How To Earn $500 A Month From Johnson & Jo...
09/12/2024 12:33:40

Johnson & Johnson offers an annual dividend yield of 3.01%. How can investors exploit its dividend yield to pocket a regula...

reported-earlier-fda-approves-johnson--johnsons-tremfya-for-adults-with-moderately-to-severely-active-ulcerative-colitis
Reported Earlier, FDA Approves Johnson & J...
09/12/2024 07:17:51

The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statist...

metals-in-tampons-fda-initiates-new-safety-measures-and-testing
Metals in Tampons: FDA Initiates New Safet...
09/11/2024 18:37:40

The FDA is investigating concerns about metals in tampons after a 2024 study. The agency is conducting an internal study and re...

sony-music-universal-music-jv-hits-johnson--johnson-with-copyright-lawsuit-over-unlicensed-music-use-covering-80-videos
Sony Music-Universal Music JV Hits Johnson...
09/11/2024 18:32:22

Johnson & Johnson is facing a lawsuit from Associated Production Music for allegedly using unlicensed music in nearly 80 vi...

johnson--johnsons-mid-stage-lung-cancer-trial-reveals-fewer-infusion-related-reactions
Johnson & Johnson's Mid-Stage Lung Cancer ...
09/11/2024 13:08:23

Johnson & Johnson announced promising Phase 2 SKIPPirr study results for Rybrevant in reducing infusion-related reactions i...

johnson--johnson-says-dexamethasone-reduces-infusion-related-reactions-in-patients-with-egfr-mutated-non-small-cell-lung-cancer-treated-with-intravenous-rybrevant
Johnson & Johnson Says Dexamethasone Reduc...
09/10/2024 21:21:15

The study, which included 40 patients, showed that prophylaxis with 8-mg dexamethasone taken for two days prior to the first in...

Core News & Articles
FDA Says Aware Of Concerns About Tampon Sa...
09/10/2024 19:00:12

- Reuters

protagonist-therapeutics-two-investigational-candidates-target-over-10b-market-bullish-analyst-opines
Protagonist Therapeutics' Two Investigatio...
09/10/2024 17:17:00

Truist Securities has initiated coverage on Protagonist Therapeutics, praising its first-in-class lead asset with promising Pha...

kenvue-set-to-pop-like-a-tylenol-gelcap-golden-cross-looms-on-stock-chart
Kenvue Set To Pop Like A Tylenol Gelcap? G...
09/10/2024 12:48:40

Kenvue Inc., owner of major brands like Tylenol, is poised for a technical knockout with a Golden Cross pattern and legal win.

cantor-fitzgerald-reiterates-overweight-on-johnson--johnson-maintains-215-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 12:53:38

Cantor Fitzgerald analyst Louise Chen reiterates Johnson & Johnson (NYSE:JNJ) with a Overweight and maintains $215 price...

reported-sunday-johnson--johnson-unveils-long-term-data-from-mariposa-study-showing-rybrevant-plus-lazcluze-outperforming-osimertinib-in-lung-cancer-treatment
Reported Sunday, Johnson & Johnson Unveils...
09/09/2024 07:26:53

New longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapy-free RYBREVANT® plus LAZCLUZE™ regimen...

dell-costar-paypal-and-a-major-health-care-stock-on-cnbcs-final-trades
Dell, CoStar, PayPal And A Major Health Ca...
09/06/2024 12:47:00

Bill Baruch of Blue Line Capital named Dell Technologies Inc. his "final trade" on CNBC's "Halftime Report."

wall-streets-most-accurate-analysts-weigh-in-on-3-health-care-stocks-with-over-3-dividend-yields
Wall Street's Most Accurate Analysts Weigh...
09/06/2024 12:21:22

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION